MS drug ozanimod, from Scripps Research, submitted for European approval

Ozanimod, a drug for multiple sclerosis originating at Scripps Research, has been submitted for European approval by Celgene.

A U.S. Food and Drug Administration marketing application is also on track for filing by the end of March, the New Jersey-based drug company said Monday. The FDA rejected…

Click to view original post

Advertise With Us